Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Ken Raymond Stories

2013-05-02 04:21:48

RICHMOND, Calif., May 2, 2013 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in new proprietary bi-functional metal-chelation technology for use in targeted radiopharmaceuticals has announced that Algeta ASA (OSE:ALGETA), a company focused on the development of novel targeted cancer therapeutics, has exercised its option to take an exclusive worldwide licence to Lumiphore's patented Lumi4(®) bi-functional chelator technology and has extended the collaboration to include...

2012-03-07 10:46:39

Berkeley Lab Researchers Developing Promising Treatment for Safely Decontaminating Humans Exposed to Radioactive Actinides The New York Times recently reported that in the darkest moments of the triple meltdown last year of the Fukushima Daiichi nuclear power plant, Japanese officials considered the evacuation of the nearly 36 million residents of the Tokyo metropolitan area. The consideration of so drastic an action reflects the harsh fact that in the aftermath of a major radiation...